Effect of Sacubitril/Valsartan Versus Angiotensin Receptor Blocker or Calcium Channel Blockers on Ambulatory Blood Pressure and Safety in Hypertensive Patients: A Meta-Analysis of Randomized Controlled Trials.

J Cardiovasc PharmacolSep 18, 2026 (epub)

Xueyi Li, Lige Gao, Wenqing Guo et al.

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis of randomized controlled trials assessed sacubitril/valsartan versus angiotensin receptor blockers (ARBs) or calcium channel blockers (CCBs) in people with hypertension. Fifteen studies involving 4824 patients were included. Compared with these active treatments, sacubitril/valsartan improved 24-hour, daytime, and nighttime ambulatory blood pressure, reduced 24-hour systolic and diastolic blood pressure variability, and increased the proportions with a dipper pattern and blood pressure control. Its adverse-event profile was similar to CCBs; versus ARBs, the 200 mg/d dose was associated with fewer serious adverse events and liver function abnormalities.

Key findings

  • Sacubitril/valsartan reduced 24-hour systolic and diastolic blood pressure variability compared with ARBs or CCBs.
  • It lowered 24-hour, daytime, and nighttime ambulatory blood pressure and improved dipper proportion and blood pressure control.
  • Both 200 and 400 mg/d doses showed superior antihypertensive efficacy in subgroup analyses.
  • Adverse events were similar to CCBs; versus ARBs, 200 mg/d was associated with fewer serious adverse events, and liver function abnormalities were reduced overall.

Why it matters

Ambulatory blood pressure and its variability provide information beyond a single clinic measurement. These pooled trial findings suggest sacubitril/valsartan can improve several ambulatory blood pressure measures compared with two commonly used antihypertensive drug classes, while showing a broadly favorable safety profile. The results may inform evaluation of this option in hypertension, although the abstract does not provide effect sizes to judge the magnitude of benefit.

What to keep in mind

The abstract does not report pooled effect sizes or confidence intervals, limiting assessment of the magnitude and precision of the reported differences.

Source

Published in J Cardiovasc Pharmacol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.